Study confirms drug given routinely during cancer treatment ineffective for most, costs $6 billion

A University of Nebraska Medical Center oncologist co-authored an article in the March 21 issue of the New England Journal of Medicine which determined the U.S. wastes an estimated $6 billion annually on popular white blood cell boosting drugs that have no medical benefits for most cancer patients using them.